Background/Aim: Limited published real-world data describe adverse events (AEs) among
patients treated for mantle-cell lymphoma (MCL). The aim of this retrospective study was to …

In view of recent therapeutic advances in mantle cell lymphoma (MCL), the aim of this
retrospective cohort analysis was to assess treatment patterns, adverse events (AEs) …

Most data on overall survival (OS) and adverse events (AEs) in patients with mantle cell
lymphoma (MCL) are from controlled trials; therefore, in this population-based study, we …

Introduction: MCL is a rare, aggressive subtype of B-cell non-Hodgkin lymphoma associated
with a poor prognosis. A comprehensive understanding of the global epidemiology and …

Introduction: In patients with mantle cell lymphoma (MCL), adverse events (AEs) can impair
patient adherence to planned therapeutic regimens. In addition, moderate to severe AEs …

Introduction There are limited data on treatment patterns, adverse events (AEs), and
economic burden in younger, commercially insured patients treated for mantle cell …

19 Background: MCL is an aggressive form of non-Hodgkin's lymphoma with an incidence of
1 in 200,000 in the United States. Limited evidence exists on real-world tx utilization, costs …

Introduction Conventional treatment for mantle cell lymphoma (MCL) patients includes
regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation …

Purpose This study assessed treatment patterns in patients with mantle cell lymphoma
(MCL) and compared health care resource utilization (HRU) and costs of ibrutinib with or …

Objectives We assessed real-world healthcare resource utilization (HRU) and costs among
US patients with relapsed or refractory mantle cell lymphoma (R/R MCL) by line of therapy …